Amiloride reduces portal hypertension in rat liver cirrhosis

Gut

Volumn 59, Issue 6, 2010, Pages 827-836

  Steib, Christian J ^a   Hennenberg, Martin ^a   Beitinger, Frigga ^a   Hartmann, Anna C ^a   Bystron, Markus ^b   De Toni, Enrico N ^a   Gerbes, Alexander L ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Klinikum Memmingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA SMOOTH MUSCLE ACTIN; AMILORIDE; CANRENOIC ACID; MOESIN; RHO KINASE; THIOACETAMIDE; THROMBOXANE B2; THROMBOXANE SYNTHASE; ZYMOSAN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIVER CIRRHOSIS; LIVER PERFUSION; MALE; NICK END LABELING; NONHUMAN; PERFUSION PRESSURE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STELLATE CELL; VASOCONSTRICTION;

AMILORIDE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CANRENOATE POTASSIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HYPERTENSION, PORTAL; KUPFFER CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; SODIUM CHANNEL BLOCKERS; THROMBOXANE A2;

EID: 77953705266     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.197756     Document Type: Article

References (43)

1. Ytting H, Moller S, Henriksen JH, et al. Prognosis in patients with cirrhosis and mild portal hypertension. Scand J Gastroenterol 2006;41:1446-53.
2. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32:930-4.
3. Bendtsen F, Krag A, Moller S. Treatment of acute variceal bleeding. Dig Liver Dis 2008;40:328-36.
4. Albillos A, Banares R, Gonzalez M, et al. The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut 2007;56:259-64.
5. Pinzani M, Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008;12:901-13, x.
6. Calvaruso V, Maimone S, Gatt A, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008;57:1722-7.
7. Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009;50:604-20.
8. Moore K. Endothelin and vascular function in liver disease. Gut 2004;53:159-61. (Pubitemid 38125496)
9. Graupera M, March S, Engel P, et al. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 2005;288:G763-70.
10. Steib CJ, Gerbes AL, Bystron M, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A2. J Hepatol 2007;47:228-38.
11. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
12. Miller AM, Masrorpour M, Klaus C, et al. LPS exacerbates endothelin-1 induced activation of cytosolic phospholipase A2 and thromboxane A2 production from Kupffer cells of the prefibrotic rat liver. J Hepatol 2007;46:276-85.
13. Lee CH, Loureiro-Silva MR, Abraldes JG, et al. Decreased intrahepatic response to alpha1-adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on kupffer cell function. J Gastroenterol Hepatol 2007;22:893-900.
14. Steib CJ, Gerbes AL. Signaling pathways in liver diseases: kupffer cells. In: Dufour J-F, Clavien P-A, eds. Signaling pathways in liver diseases. Heidelberg: Springer Verlag, 2009.
15. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006;55:1296-305.
16. Hennenberg M, Trebicka J, Sauerbruch T, et al. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-14.
17. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53.
18. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-54.
19. Hennenberg M, Trebicka J, Stark C, et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009;157:258-70.
20. Benedetti A, Di Sario A, Casini A, et al. Inhibition of the Na(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology 2001;120:545-56. (Pubitemid 32147652)
21. Caligiuri A, De Franco RM, Romanelli RG, et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 2003;124:504-20.
22. Laleman W, Vander EI, Zeegers M, et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006;36:242-9.
23. Bilzer M, Paumgartner G, Gerbes AL. Glutathione protects the rat liver against reperfusion injury after hypothermic preservation. Gastroenterology 1999;117:200-10.
24. Bilzer M, Baron A, Schauer R, et al. Glutathione treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation. Digestion 2002;66:49-57.
25. Schauer RJ, Gerbes AL, Vonier D, et al. Induction of cellular resistance against Kupffer cell-derived oxidant stress: a novel concept of hepatoprotection by ischemic preconditioning. Hepatology 2003;37:286-95.
26. Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007;45:495-506.
27. Van de Casteele M, Hosli M, Sagesser H, et al. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. J Hepatol 1999;31:300-5.
28. Haussinger D, Brodde OE, Starke K. Alpha-adrenoceptor antagonistic action of amiloride. Biochem Pharmacol 1987;36:3509-15.
29. Oberti F, Pilette C, Rifflet H, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997;26:1363-71.
30. Van de Casteele M, Van Roey G, Nevens F, et al. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996;24:1492-6.
31. Asahina K, Tsai SY, Li P, et al. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 2009;49:998-1011.
32. Cassiman D, Libbrecht L, Desmet V, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002;36:200-9.
33. Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol 2002;37:527-35.
34. Mabuchi A, Mullaney I, Sheard PW, et al. Role of hepatic stellate cell/hepatocyte interaction and activation of hepatic stellate cells in the early phase of liver regeneration in the rat. J Hepatol 2004;40:910-16.
35. Nanji AA, Rahemtulla A, Maio L, et al. Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease. J Pharmacol Exp Ther 1997;282:1037-43.
36. Yokoyama Y, Nimura Y, Nagino M, et al. Role of thromboxane in producing hepatic injury during hepatic stress. Arch Surg 2005;140:801-7.
37. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-86.
38. Angeli P, Dalla PM, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;19:72-9.
39. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003;38:258-66.
40. Sugano S, Kawafune T, Okajima T, et al. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998;43:893-7.
41. Bolondi L, Piscaglia F, Gatta A, et al. Effect of potassium canrenoate, an antialdosterone agent, on incidence of ascites and variceal progression in cirrhosis. Clin Gastroenterol Hepatol 2006;4:1395-402.
42. Klein CP. [Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?]. Dtsch Med Wochenschr 1985;110:1774-6.
43. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65.